#Sweden #Stockholm #Sobi #growth #financial report

Sobi Reports Impressive Q1 2026 Results

On April 28, 2026, Swedish Orphan Biovitrum AB (Sobi) released its financial report for the first quarter of 2026, showcasing remarkable growth across key revenue segments. Sobi is a respected global biopharmaceutical company that aims to unlock the potential of innovative solutions for those living with rare diseases. The report revealed that the overall revenue for Q1 2026 reached SEK 7,184 million, marking a 24% increase when considering constant exchange rates, and an 11% rise at actual rates, compared to the previous year.

Growth in Haematology and Immunology

A significant factor in this financial success is the performance of Sobi's haematology portfolio, which saw revenues surge by 24% to SEK 5,186 million. This growth was largely driven by outstanding sales of Sobi’s key products: Altuvoct, which contributed SEK 1,240 million in sales compared to SEK 455 million in Q1 2025, and Doptelet, which generated SEK 1,433 million in revenue, climbing from SEK 1,129 million.

In addition to haematology, Sobi's immunology segment also reported a 24% increase, reaching SEK 1,643 million. This sector's growth stemmed from strong sales figures for Gamifant, earning SEK 734 million from SEK 582 million last year, and Kineret, which brought in SEK 779 million against SEK 735 million in Q1 2025.

Strategic Portfolio Performance

The strategic portfolio of Sobi delivered an outstanding performance as well, growing by an exceptional 55% at constant exchange rates to SEK 4,524 million from SEK 3,255 million in the prior year. This growth reflects Sobi’s ability to capitalize on increasing demand for innovative treatments and underscores the effectiveness of its ongoing strategies for expansion.